Research

BARE is currently in the beginning stages of collaborating with other key organizations and individuals within the Biliary Atresia community.  

Clinical Trials

BOLD Clinical Trial

The BOLD research study, initiated by our partners at Albireo Pharma, is the first Phase 3 study to evaluate the safety and efficacy of the medication odevixibat in babies with biliary atresia who have undergone a Kasai procedure.

What is odevixibat?

Odevixibat is a potent, non-systemic ileal bile acid transport inhibitor (IBATi) designed to treat rare pediatric cholestatic liver diseases such as biliary atresia. Odevixibat is a once-daily oral medication which may be emptied into breastmilk, formula, or certain soft foods.

For more information on this clinical trial, please visit www.boldtrial.com

Albireo_Logo_RGB300dpi_edited.png

EMBARK Clinical Trial

The EMBARK research study, initiated by our partners at Mirum Pharma, is a Phase 2b study evaluating LIVMARLI (maralixibat) in pediatric patients with biliary atresia.

What is maralixibat?

Maralixibat is a medication that targets and temporarily blocks something in your body called the ileal bile acid transporter (IBAT). In doing so, it reduces the amount of bile acids in the liver and blood by interrupting bile acids from going back into the liver and increases the amount of bile acids that are excreted (eliminated) from the body in feces.

For more information on this clinical trial, please visit Mirum Pharma

Mirum_Inline_FullColor_RGB_edited.png